PCSK9 and atherosclerosis: In black carriers, a 28% LDL-C reduction was associated with an 88% lower CAD risk, while white carriers with a 15% LDL-C decrease had a 47% risk reduction, reinforcing the causal link between LDL-C and CAD and identifying PCSK9 inhibition as a promising therapeutic target for ASCVD prevention [82].